Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.5705
+0.2229 (64.13%)
At close: Mar 28, 2025, 4:00 PM
0.5740
+0.0035 (0.61%)
After-hours: Mar 28, 2025, 4:35 PM EDT
Lexicon Pharmaceuticals Revenue
In the year 2024, Lexicon Pharmaceuticals had annual revenue of $31.08M with 2,481.48% growth. Lexicon Pharmaceuticals had revenue of $26.55M in the quarter ending December 31, 2024, with 3,682.62% growth.
Revenue (ttm)
$31.08M
Revenue Growth
+2,481.48%
P/S Ratio
3.58
Revenue / Employee
$301,757
Employees
103
Market Cap
206.23M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
LXRX News
- 6 hours ago - Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal - Market Watch
- 7 hours ago - Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
- 9 hours ago - Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 - GlobeNewsWire
- 21 days ago - Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 21 days ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 23 days ago - Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - GlobeNewsWire
- 25 days ago - Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - GlobeNewsWire